DUOLITH® SD1 T-TOP »ultra« – The New Focused Shock Wave Generation
Explore the advanced features of the DUOLITH® SD1 T-TOP »ultra« shock wave system, featuring the SEPIA® handpiece renowned for its superior craftsmanship and ergonomic design. This cutting-edge technology facilitates effortless and precise treatment directly at the patient, optimizing workflow efficiency.
The SEPIA® handpiece streamlines focused shock wave therapy with integrated control elements for seamless adjustment of frequency and energy levels during treatments. Its universal compatibility with all DUOLITH® SD1 »ultra« systems ensures cost-effective maintenance by enabling easy coil replacement, reducing downtime and operational costs.
Key Features and Benefits:
- Direct and efficient patient treatment, enhancing clinical outcomes
- Integrated control elements within the SEPIA® handpiece for simplified treatment customization
- Reduced operational costs due to easy coil replacement, ensuring optimal performance and longevity of the system
- Focal zone depth range of 0 – 65 mm, allowing precise targeting of treatment areas
- Therapeutic effectiveness with up to 125 mm penetration depth, achieving comprehensive tissue treatment
- Expandable functionality with modular extensions, offering scalability and future-proofing for evolving clinical needs
DUOLITH® SD1 T-TOP »ultra«: shock wave treatment for erectile dysfunction (ED)* and urological pain therapy
The DUOLITH® SD1 T-TOP »ultra« presents a shock wave therapy system specifically designed for treating erectile dysfunction (ED), induratio penis plastica (IPP), and chronic pelvic pain syndrome (CPPS) of vascular origin. Scientific studies validate the efficacy of focused shock waves for these conditions. Click the Learn More button for detailed references.
The effectiveness of the DUOLITH® SD1 T-TOP »ultra« is attributed to its individually selectable, high dynamic, and optimal energy range, coupled with adjustable therapeutic depth of focus. This allows for easy treatment of deep-lying areas with precise accuracy. The technical features highlight the superior performance of this therapy system. Additionally, the focused handpiece SEPIA® boasts an anatomically shaped stand-off for perfect adaptation to the penile anatomy during ED or IPP treatment. This system’s depth of focus enables targeted shock wave application from one side of the penis, ensuring optimized treatment outcomes.
Induratio penis plastica (IPP) treatment with shock waves
Induratio penis plastica (IPP), also known as Peyronie’s disease, is an acquired and generally progressive condition of the penis. Most men notice the presence of the disease when they feel thickened nodules (so-called plaques) under the skin of the penis. As the disease progresses, pain may occur with or without an erection and the penis becomes curved during an erection, which can make it difficult or impossible to have sexual intercourse.
When treating IPP/Peyronie’s disease, the pain points in the penis are treated with extracorporeal shock waves. In a pilot study , shock waves were delivered to the nonerect penis once a week for a period of five weeks. 18 months after the last shock wave session, the deviation angle had decreased from 59.3° ± 38.1° to 49.3° ± 32.5° (N = 24; P = 0.1496). Pain during erection disappeared in 15 of 17 patients and was reduced in one other patient (P < 0.0001). After shock wave treatment,
15 patients achieved satisfactory sexual intercourse (before treatment: six patients). In 2009, a clinical trial with 100 patients concluded that ESWT leads to resolution of pain and improves both erectile function and quality of life. At 12-week follow-up, mean VAS score, mean IIEF-5 score, and mean QoL score improved significantly in patients receiving shock wave therapy. After 24 weeks, mean IIEF-5 score and mean QoL score were stable in the shock wave group, while the mean VAS score decreased even further. »Interestingly, after 24 wk, mean plaque size and mean curvature degree were significantly higher in the placebo group when compared with both baseline and ESWT values«. The authors of a systematic review published in 2017 also came to the conclusion that ESWT may resolve pain in patients with IPP/Peyronie’s disease.